MI-EATON
16.11.2021 12:32:13 CET | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has demonstrated cylinder deactivation (CDA) as an effective technology for meeting future global emissions requirements for diesel-engine powered commercial vehicles. To date, the technology has been evaluated with a close-coupled selective catalytic reduction (SCR) aftertreatment system with and without a 48-volt electric heater.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005234/en/
“Our CDA technology has proven it can help our customers meet increasingly strict emissions regulations for diesel engines,” said Christopher Mancuso, business unit director, Engine Air Management, Eaton’s Vehicle Group. “This comes at a time when many global manufacturers are determining what technologies they will leverage in next-generation vehicles to reduce harmful emissions.”
New emissions regulations spearheaded by the California Air Resources Board (CARB), U.S. Environmental Protection Agency (EPA) and European Commission (EC) are slated for adoption in coming years. These agencies, in concert with other national and international regulators, seek to significantly reduce greenhouse gas (GHG) emissions and harmful air pollutants produced primarily by heavy-duty trucks, vans and buses.
Rapid catalyst warm-up essential
Eaton partnered with the Southwest Research Institute (SwRI), one of the oldest and largest independent, nonprofit, applied research and development organizations in the U.S., to demonstrate the feasibility of its Vehicle Group’s technology. The findings demonstrate that using CDA and a close-coupled SCR catalyst reduced both nitrous oxide (NOx) and carbon dioxide (CO2 ) emissions with fuel consumption savings of up to 40% at idle.
Previous results utilizing CDA and a close-coupled SCR catalyst demonstrated compliance to forthcoming U.S. regulations for NOx and CO2 emissions for diesel commercial vehicles. Testing with the new low-load cycle (LLC) resulted in a 5% drop in CO2 while dramatically reducing NOx. The assessment was developed by CARB to replicate real-world urban tractor and vocational vehicle operations at low engine loads.
Eaton’s 2021 testing with SwRI showed further advancement, dropping NOx levels by 99.4% on the composite federal test procedure (FTP) and lowering the LLC NOx to well within current guidelines. Notably, using the same aftertreatment system with the addition of a 48-volt electric heater located upstream of the SCR further achieved a reduction in CO2 .
CDA technology can benefit vehicle manufacturers facing tightening emissions standards in Europe as well. The next set of requirements, known as Euro VII for heavy-duty trucks, is targeted for the second part of the decade. In the U.S., CARB is introducing more stringent regulations as soon as 2024, while the EPA has circled 2027 to begin applying stricter emissions limits on new-model heavy-duty vehicles. Collectively, these standards are designed to reduce tailpipe NOx emissions up to 90%, accelerating the need for global engine manufacturers to employ additional emissions-reduction strategies such as electric catalyst heating. This technology is an example of how Eaton is progressing toward achieving its 2030 Sustainability Targets . By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
